ResearcherDuke UniversityNo recent work listed
Partha Ray
Matched on ORCID iD 0000-0002-7075-5463; OpenAlex author ID A5012045092. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 8
- Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metasta… Co-author DOI 10.1136/jitc-2022-006133↗
- Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model. Co-author DOI 10.1007/s12672-022-00483-4↗
- Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. Co-author DOI 10.1016/j.surg.2020.04.059↗
- Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. First author DOI 10.1158/2326-6066.cir-19-0101↗
- A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation. First author DOI 10.3791/57265↗
- Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. Co-author DOI 10.1089/nat.2013.0439↗
- Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Co-author DOI 10.1089/nat.2012.0353↗
- Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. Co-author DOI 10.1172/jci62385↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rebekah Ruth White · 8 shared papers, 2012–2023 · strength 0.77
- Paper Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic imm… DOI 10.1136/jitc-2022-006133↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation. DOI 10.3791/57265↗
- Jayanth S. Shankara Narayanan · 5 shared papers, 2018–2023 · strength 0.64
- Paper Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic imm… DOI 10.1136/jitc-2022-006133↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation. DOI 10.3791/57265↗
- Suna Erdem · 3 shared papers, 2020–2023 · strength 0.42
- Paper Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic imm… DOI 10.1136/jitc-2022-006133↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Diego A. Vicente · 3 shared papers, 2019–2022 · strength 0.36
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Paper Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Mur… DOI 10.1158/2326-6066.cir-19-0101↗
- Steven C. Katz · 2 shared papers, 2020–2022 · strength 0.26
- Stephen Philip Schoenberger · 2 shared papers, 2019–2023 · strength 0.26
- Paper Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic imm… DOI 10.1136/jitc-2022-006133↗
- Paper Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Mur… DOI 10.1158/2326-6066.cir-19-0101↗
- Hervé Tiriac · 1 shared paper, 2023 · strength 0.16
- Bruce A. Sullenger · 3 shared papers, 2012–2013 · strength 0.13
- Paper Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its po… DOI 10.1089/nat.2013.0439↗
- Paper Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancre… DOI 10.1172/jci62385↗
- Paper Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. DOI 10.1089/nat.2012.0353↗
- Ibtehaj A. Naqvi · 1 shared paper, 2018 · strength 0.12
- Benedict A. Capacio · 1 shared paper, 2020 · strength 0.11
- Na Li · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.